Media stories about Ligand Pharmaceuticals (NASDAQ:LGND) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.8601160059939 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern’s scoring:
Several equities research analysts have recently weighed in on LGND shares. HC Wainwright set a $169.00 target price on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Craig Hallum upped their target price on shares of Ligand Pharmaceuticals from $170.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Roth Capital upped their target price on shares of Ligand Pharmaceuticals from $158.00 to $171.00 and gave the stock a “buy” rating in a report on Monday, February 26th. BidaskClub lowered shares of Ligand Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, Zacks Investment Research raised shares of Ligand Pharmaceuticals from a “hold” rating to a “buy” rating and set a $171.00 target price on the stock in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $161.00.
Ligand Pharmaceuticals (LGND) opened at $171.85 on Friday. The stock has a market cap of $3,772.45, a PE ratio of 336.97, a P/E/G ratio of 1.80 and a beta of 1.10. The company has a current ratio of 0.99, a quick ratio of 0.97 and a debt-to-equity ratio of 0.05. Ligand Pharmaceuticals has a 52-week low of $102.56 and a 52-week high of $184.79.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $1.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.19 by $0.12. The business had revenue of $50.50 million for the quarter, compared to the consensus estimate of $49.39 million. Ligand Pharmaceuticals had a net margin of 8.90% and a return on equity of 14.44%. The firm’s quarterly revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.25 EPS. analysts forecast that Ligand Pharmaceuticals will post 3.59 earnings per share for the current year.
In related news, Director Stephen L. Sabba sold 925 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total transaction of $126,956.25. Following the transaction, the director now owns 26,985 shares in the company, valued at approximately $3,703,691.25. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John W. Kozarich sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $145.00, for a total transaction of $362,500.00. Following the transaction, the director now owns 33,149 shares in the company, valued at approximately $4,806,605. The disclosure for this sale can be found here. In the last quarter, insiders have sold 100,512 shares of company stock worth $15,879,684. 8.30% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/03/18/ligand-pharmaceuticals-lgnd-earning-somewhat-favorable-news-coverage-analysis-finds.html.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.